Valuation : ARYx Therapeutics, Inc.

Market Cap	9.03M 7.79M 7.3M 6.66M 12.55M 863M 12.59M 86.6M 33.79M 436M 33.92M 33.18M 1.45B	P/E 2008	-1.76x	P/E 2009	-2.66x
Enterprise Value	11.41M 9.83M 9.22M 8.41M 15.85M 1.09B 15.9M 109M 42.66M 550M 42.82M 41.89M 1.82B	EV / Sales 2008	4,019,605x	EV / Sales 2009	-
Free-Float	100%	Yield 2008 *	-	Yield 2009	-

* Estimated data More valuation ratios

Press Releases : ARYx Therapeutics, Inc.

10/03/11	ARYX THER : ARYx Therapeutics Informed of Additional Delay by FDA and Begins Wind-Down of Operations	BU
24/12/10	ARYX THER : ARYx Therapeutics Clarifies Current Status of Operations	BU
21/12/10	ARYX THER : ARYx Therapeutics to Transfer to the NASDAQ Capital Market	BU
16/12/10	ARYX THER : ARYx Therapeutics Provides Update on Company Status	BU
15/11/10	ARYX THER : ARYx Therapeutics Reports Third Quarter Results	BU

More press releases

ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Real-time OTC Markets 11:47:07 26/06/23 pm AEST			5-day change	1st Jan Change
0.001200 ^USD	+1,100.00%		+119,900.00%	+119,900.00%

1 week	+119,900.00%
Current month	+119,900.00%

1 day	+1,100.00%
1 week	+119,900.00%
Current month	+119,900.00%
1 month	+119,900.00%
3 months	+119,900.00%
6 months	+119,900.00%
Current year	+119,900.00%

3 years	0		0
5 years	0		0
10 years	0		0.05

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARYX THERAPEUTICS, INC.	+1,100.00%	+119,900.00%	+119,900.00%	+119,900.00%	33
WUXI APPTEC CO., LTD.	-1.59%	-6.25%	+64.99%	+99.09%	70.64B
ARGENX SE	-1.34%	-0.75%	+48.56%	+90.63%	66.11B
BIONTECH SE	-8.05%	-11.94%	+0.71%	-14.94%	27.98B
INSMED INCORPORATED	-2.50%	-5.61%	-12.04%	+449.12%	26.51B
WUXI BIOLOGICS (CAYMAN) INC.	+0.30%	+2.03%	+59.48%	+14.21%	26.44B
PHARMAESSENTIA CORPORATION	-0.96%	+12.36%	+280.38%	+439.54%	20.4B
GENMAB A/S	-0.51%	+0.23%	+33.71%	-18.02%	20.17B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.91%	-3.47%	+11.03%	+508.52%	15.99B
EXELIXIS, INC.	-1.40%	+0.78%	+43.80%	+145.72%	13.69B
Average	+108.27%	+1.00%	+12,043.06%	+12,161.39%	28.79B
Weighted average by Cap.	-1.91%	+1.23%	+56.44%	+151.38%

ARYx Therapeutics, Inc. Stock

Stocks

ARYX

US0433871094

Biotechnology & Medical Research

Valuation : ARYx Therapeutics, Inc.

Press Releases : ARYx Therapeutics, Inc.

Quotes and Performance

Price Extremes

Bio Therapeutic Drugs

Financials

Company Profile

	2008	2009
Net sales	19.72 17 15.94 14.55 27.4 1.89K 27.49 189.06 73.77 951.59 74.05 72.44 3.16K	-
Net income	-31.22M -26.9M -25.22M -23.02M -43.37M -2.98B -43.51M -299M -117M -1.51B -117M -115M -4.99B	-33.17M -28.58M -26.8M -24.46M -46.08M -3.17B -46.23M -318M -124M -1.6B -125M -122M -5.31B
Net Debt	-29.9 -25.77 -24.16 -22.06 -41.55 -2.86K -41.68 -286.65 -111.84 -1.44K -112.28 -109.84 -4.78K	2.37 2.04 1.92 1.75 3.29 226.61 3.3 22.73 8.87 114.39 8.9 8.71 379.3